Etanercept treatment in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 300-304

  Rowin, Julie ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Etanercept; Myasthenia gravis; Treatment

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; ETANERCEPT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; ERYTHEMA; HEADACHE; HUMAN; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NONHUMAN; PROTEIN BLOOD LEVEL; RASH;

EID: 45549096108     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.028     Document Type: Conference Paper

References (35)

1. Vincent, A. 2006. Immunology of disorders of neuromuscular transmission. Acta Neurol. Scand. Suppl. 183 : 1 7.
2. Saperstein, D.S. & R.J. Barohn. 2004. Management of myasthenia gravis. Semin. Neurol. 24 : 41 48.
3. Kissel, J.T. et al. 1986. Azathioprine toxicity in neuromuscular disease. Neurology 36 : 35 39.
4. Boumpas, D.T. et al. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119 : 1198 1208.
5. Palace, J. et al. 1998. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50 : 1778 1783.
6. Hohlfeld, R. et al. 1988. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38 : 258 261.
7. Tindall, R.S.A. et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681 : 539 551.
8. Ciafaloni, E. et al. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56 : 97 99.
9. Meriggioli, M.N. et al. 2003. Mycophenolate mofetil for myasthenia gravis: a double-blind placebo-controlled pilot trial. Ann. N.Y. Acad. Sci. 998 : 494 999.
10. Meriggioli, M.N. et al. 2003. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61 : 1438 1440.
11. Sanders, D.B. & Z.A. Siddiqi. 2008. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorder: 11th International Conference. In Press.
12. Kremer, J.M. 2001. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med. 134 : 695 706.
13. Hochberg, M.C. 2003. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 (Suppl 2 ii13 16.
14. Brennan, F.M. & M. Feldmann. 1992. Cytokines in autoimmunity. Curr. Opin. Immunol. 4 : 754 759.
15. Chu, C.Q. et al. 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34 : 1125 1132.
16. Bongioanni, P. et al. 1999. T-cell tumor necrosis factor-alpha binding in myasthenic patients. J. Neuroimmunol. 93 : 203 207.
17. Li, H.L. 1998. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. J. Neurol. Sci. 161 : 40 46.
18. Matusevicius, D. et al. 1996. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71 : 191 198.
19. Zhang, G.X. et al. 1997. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 73 : 175 182.
20. Christadoss, P. & E. Goluszko. 2002. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor FC protein. J. Neuroimmunol. 122 : 186 190.
21. Zhang, G. X., V. Navikas & H. Link. 1997. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 20 : 543 551.
22. Moreland, L.W. et al. 1997. Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 : 141 147.
23. Moreland, L.W. et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann. Intern. Med. 130 : 478 486.
24. Brandt, J. et al. 2003. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis. Rheum. 48 : 1667 1675.
25. Moreland, L.W. et al. 2001. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 28 : 1238 1244.
26. Moreland, L.W. et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130 : 478 486.
27. Rowin, J. et al. 2004. A pilot trial of etanercept in the treatment of steroid-dependent, generalized autoimmune myasthenia gravis. Neurology 62 (Suppl 5 A185.
28. Wolfe, G.I. et al. 1999. Myasthenia gravis activities of daily living profile. Neurology 52 : 1487 1489.
29. Barohn, R.J. et al. 1998. Reliability testing of the quantitative myasthenia gravis score. Ann. N.Y. Acad. Sci. 841 : 769 772.
30. Sanders, D.B., B. Tucker-Lipscomb, J.M. Massey, et al. 2003. A simple manual muscle test for myasthenia gravis. Validation and comparison with the QMG score. Ann. N.Y. Acad. Sci. 998 : 440 444.
31. Moreland, L.W. et al. 2006. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. 33 : 854 861.
32. Dixon, W.G. et al. 2006. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis. Rheum. 54 : 2368 2376.
33. Ornetti, P. et al. 2006. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 23 : 855 860.
34. Desai, S.B. et al. 2006. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. 20 : 757 790.
35. Tuzun, E. et al. 2005. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J. Autoimmun. 24 : 261 268.